Scores by echosens
Enhance FibroScan® liver disease assessment with biological markers
CAP™ (Controlled Attenuation Parameter) is the non-invasive reference parameter to diagnose and monitor liver steatosis.
There is a silent epidemic of fatty liver disease in the general population, called NAFLD/NASH. The main causes of fatty liver disease are excessive alcohol consumption and/or poor diet and sedentary lifestyle.
If patients remain undiagnosed and untreated, they may go on to develop irreversible cirrhosis of the liver. If treated early with diet and lifestyle changes, the disease can be reversible.
Most patients with the presence of a metabolic syndrome.
Risk factors and predictors of NAFLD
CAP™ is unique, patented and validated for liver disease management2,3.
CAP™ is a guiding point for doctors and patients to improve monitoring of lifestyle change and therapeutic intervention.
CAP™ is a quantitative surrogate of liver steatosis expressed in decibel per meter (db/m).
Both LSM by VCTE™ and CAP™ are measured simultaneously without lengthening the examination time.
CAP™ is available on the three FibroScan® probes (S+*, M+ and XL+).
CAP™ provides a convenient and patient-friendly method to assess lipid turnover during lifestyle and dietary interventions to combat NAFLD.
Lifestyle modification improves the hepatic steatosis, and CAP™ can be used to detect the improvement of hepatic steatosis during follow-up in patients with NAFLD on lifestyle modification.
The dietary intervention has a positive impact on CAP™.
*CAP™ is not available on S probe in all countries.
Indications for use
The Shear wave speed and stiffness measurements may be used as an aid to clinical management of adult patients with liver disease.
The shear wave speed and stiffness, and CAP may be used as an aid to diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver.
Shear wave speed and stiffness, and CAP* may be used as an aid in the clinical management of pediatric patients with liver disease.
* CAP for pediatric patients with liver disease is only available with SmartExam capability.
References are available in our bibliography.